HALIFAX, Nova Scotia, April 23, 2020 (GLOBE NEWSWIRE) — MedMira Inc. (MedMira) (TSXV: MIR), announced today that it had submitted the notification for the Emergency Use Authorization application offered by the U.S. Food and Drug Administration (FDA) for its newest member of its Reveal line of products for antibody testing. The FDA policy announced on March 16, 2020 permits MedMira to begin U.S. sales of REVEALCOVID-19TM total antibody test immediately while it awaits FDA clearance under Emergency Use Authorization (EUA).“Completion of the validation, and the notification to the FDA is a key step in our efforts to bring our newest test to market in an attempt to help the COVID-19 pandemic situations. The Company’s full submission for EUA is currently in preparation.” said Hermes Chan, CEO, “Our Rapid Vertical Flow® technology, with no timer or reader requirement, allows all our rapid tests to be used in various settings and provides an immediate clearly visible result.”MedMira, with its over 20 years of experience, has a proven track record to provide high quality, simple and rapid tests for a number of diseases. REVEALCOVID-19TM total antibody test can be used with whole blood, serum or plasma and is also ideal for batch testing in laboratory settings, meeting the needs of all possible users across a broad range of testing environments. This versatility and speed will enable fast and reliable results for detection of any antibodies such as IgM, IgG and IgA from the SARS-COV-2 virus.About MedMira
Bay Street News